# EDGAR Filing Document

**Accession Number:** 0001955972
**File Stem:** 0000059478-23-000002
**Filing Date:** 2023-1
**Character Count:** 6557
**Document Hash:** 81be061ad79ecfe5423d37f108605743
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000059478-23-000002.hdr.sgml**: 20230103

**ACCESSION NUMBER**: 0000059478-23-000002

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20221225

**FILED AS OF DATE**: 20230103

**DATE AS OF CHANGE**: 20230103

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Dozier Eric
- **CENTRAL INDEX KEY:** 0001955972

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-06351
- **FILM NUMBER:** 23502744

**MAIL ADDRESS:**
- **STREET 1:** LILLY CORPORATE CENTER
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46285
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ELI LILLY & Co
- **CENTRAL INDEX KEY:** 0000059478
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 350470950
- **STATE OF INCORPORATION:** IN
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** LILLY CORPORATE CTR
- **STREET 2:** DROP CODE 1094
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46285
- **BUSINESS PHONE:** 3172762000

**MAIL ADDRESS:**
- **STREET 1:** LILLY CORPORATE CENTER
- **STREET 2:** DROP CODE 1094
- **CITY:** INDIANAPOLIS
- **STATE:** IN
- **ZIP:** 46285

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LILLY ELI & CO
- **DATE OF NAME CHANGE:** 19941024

## Ex-24

```
<pre>
LIMITED POWER OF ATTORNEY

For Managing Form ID and Executing Forms 3, 4 and 5

I hereby authorize and designate (i) Anat Hakim, Lilly Corporate Center, Indianapolis, Indiana, (ii) Christopher Anderson, Lilly Corporate Center, Indianapolis, Indiana, and (iii) Jonathan Groff, Lilly Corporate Center, Indianapolis, Indiana, each signing severally and not jointly, with full power of substitution, to take the following actions on my behalf regarding my transactions and holdings in the common stock and other equity securities of Eli Lilly and Company as required by Section 16 of the Securities Exchange Act of 1934 and the rules thereunder (collectively, "Securities Laws"):

1.    as applicable, prepare, execute in my name and on my behalf, and submit to the United States Securities and Exchange Commission (the "SEC") a Form ID, Uniform Application for Access Codes to File on EDGAR and any other documents necessary or appropriate to obtain or maintain codes and passwords enabling me to make electronic filings with the SEC of reports required by the Securities Laws; and

2.    sign and file with the SEC on my behalf Forms 3, 4, and 5 (including any amendments thereto).

The undersigned hereby agrees that each such attorney-in-fact may rely entirely on information furnished orally or in writing by or at my direction to the attorney-in-fact.

This authorization and designation shall remain in effect until a written revocation is signed by me and provided to Eli Lilly and Company and the attorneys-in-fact listed above.

IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of the date written below.

November 2, 2022

/s/ Eric Dozier
</pre>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Dozier Eric<br><sub>(Last) (First) (Middle)</sub><br>LILLY CORPORATE CENTER<br><sub>(Street)</sub><br>INDIANAPOLIS, IN 46285<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>ELI LILLY & Co [ LLY ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2022-12-25 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EVP, HR & Diversity_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 4100 | D |  |
| Common Stock | 90 | I | 401(k) |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | 2023-03-01 | 2023-03-01 | Common Stock | 1602.0 | <sup>(1)</sup> | D |  |
| Restricted Stock Unit | 2025-03-01 | 2025-03-01 | Common Stock | 2403.0 | <sup>(1)</sup> | D |  |
| Restricted Stock Unit | 2024-11-01 | 2024-11-01 | Common Stock | 1534.0 | <sup>(1)</sup> | D |  |
| Restricted Stock Unit | 2026-11-01 | 2026-11-01 | Common Stock | 2300.0 | <sup>(1)</sup> | D |  |

---

### Footnotes:

(1) Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Jonathan Groff for Eric Dozier, pursuant to authorization attached  
**Date:** 2023-01-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**